Biosimilars: What Will The Second Advisory Committee Tell Us?
This article was originally published in The Pink Sheet Daily
Executive Summary
Celltrion will have the most at stake next week, but future sponsors – and FDA itself – could learn a lot about how reviews of these new products work.